<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Pediatric <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group (POG) studies 9426 and 9425 evaluated <z:chebi fb="0" ids="50223">dexrazoxane</z:chebi> (DRZ) as a cardiopulmonary protectant during treatment for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated incidence and risk factors of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and second malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (SMNs) </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Treatment for low- and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> with <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="3139">bleomycin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="4911">etoposide</z:chebi> (ABVE) or dose-intensified ABVE with <z:chebi fb="0" ids="8382">prednisone</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (ABVE-PC), respectively, was followed by low-dose radiation </plain></SENT>
<SENT sid="3" pm="."><plain>The number of chemotherapy cycles was determined by rapidity of the initial response </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were assigned randomly to receive DRZ (n = 239) or no DRZ (n = 239) concomitantly with chemotherapy to evaluate its potential to decrease adverse cardiopulmonary outcomes </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Ten patients developed SMN </plain></SENT>
<SENT sid="6" pm="."><plain>Six of eight patients developed <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e>, and both <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> (<z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> and <z:hpo ids='HP_0002895'>papillary thyroid carcinoma</z:hpo>) occurred in recipients of DRZ </plain></SENT>
<SENT sid="7" pm="."><plain>Eight patients with SMN were first events </plain></SENT>
<SENT sid="8" pm="."><plain>With median 58 months' follow-up, 4-year cumulative incidence rate (CIR) for <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> was 2.55% +/- 1.0% with DRZ versus 0.85% +/- 0.6% in the non-DRZ group (P = .160) </plain></SENT>
<SENT sid="9" pm="."><plain>For any SMN, the CIR for DRZ was 3.43% +/- 1.2% versus CIR for non-DRZ of 0.85% +/- 0.6% (P = .060) </plain></SENT>
<SENT sid="10" pm="."><plain>Among patients receiving DRZ, the standardized incidence rate (SIR) for <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> was 613.6 compared with 202.4 for those not receiving DRZ (P = .0990) </plain></SENT>
<SENT sid="11" pm="."><plain>The SIR for <z:hpo ids='HP_0000001'>all</z:hpo> SMN was 41.86 with DRZ versus 10.08 without DRZ (P = .0231) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: DRZ is a <z:chebi fb="0" ids="50750">topoisomerase II inhibitor</z:chebi> with a mechanism distinct from <z:chebi fb="0" ids="4911">etoposide</z:chebi> and <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> </plain></SENT>
<SENT sid="13" pm="."><plain>Adding DRZ to ABVE and ABVE-PC may have increased the incidence of SMN and <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> </plain></SENT>
</text></document>